论文部分内容阅读
目的：探索洛伐他汀对糖尿病合并高脂血症的降脂疗效。方法：糖尿病合并高脂血症３０例（男性１０例，女性２０例；年龄５４±ｓ１４ａ），采用洛伐他汀片２０ｍｇ，ｑｄ共８ｗｋ。结果：与治疗前相比，服药４和８ｗｋ后分别ＴＣ降低２６％，２５％；ＴＧ降低５６％，５６％；ＬＤＬ－ｃｈ降低３１％，３２％；ＴＣ－ＨＤＬ－Ｃｈ／ＨＤＬ－ｃｈ降低３２％，３４％。治疗前后差异非常显著（Ｐ＜０．０１）。治疗过程见７例ＡＬＴ轻度升高，其中６例停药或护肝疗法恢复正常，１例持续轻度升高。未发现其他不良反应。结论：洛伐他汀对糖尿病合并高脂血症病人有较好降脂疗效，但对有肝病史者慎用。
Objective: To investigate the lipid-lowering effect of lovastatin on diabetic hyperlipidemia. Methods: Thirty diabetic patients with hyperlipidemia (10 males and 20 females; age 54 ± s14a) were treated with lovastatin tablets 20 mg qd for 8 weeks. Results: Compared with those before treatment, TC decreased by 26% and 25% after 4 and 8 weeks of treatment, respectively; TG decreased by 56% and 56%; LDL-ch decreased by 31% and 32% respectively; TC-HDL-Ch / HDL- 32%, 34%. Before and after treatment, the difference was significant (P <0.01). The course of treatment, see 7 cases of mildly elevated ALT, of which 6 cases of withdrawal or hepatoprotective therapy returned to normal, 1 case sustained mild increase. No other adverse reactions were found. Conclusion: Lovastatin has a better lipid-lowering effect on patients with diabetes mellitus and hyperlipidemia, but caution should be used when there is a history of liver disease.